Joint Corp. (The) (JYNT)
NASDAQHealth CareMedical - Care FacilitiesSnapshot 2026-09-04
$8.32+0.48%
Close 2026-09-04 · 1-day change
NASDAQHealth CareMedical - Care FacilitiesSnapshot 2026-09-04
QuarterlyIQ Insights · JYNT
Price, fair value, and the multiples that frame it on the same time axis. Scroll over the price chart to zoom.
Daily closes. Earnings/event dots inline.
A consensus fair price across 10 valuation methods, at three horizons. As of 2026-09-04. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
We take the 12-month fair value above and grade our own number — how the market prices this name versus what we'd justify, and where the two diverge.
At $8.32 the market pays 32× p/e — above the 23× p/e peer median but in line with its own 41× history. That premium reflects a durable franchise our peer-anchored $5.00 fair value understates; treat the 'expensive vs peers' read with medium confidence. Not investment advice.
One valuation read at a 12-month horizon, plus how price compares to peers and the company's own history.
Score 100 = cheapest in the cohort, 0 = richest. Bars are filled left-to-right based on the peer-relative score (or PEG/self-history where shown).
Each method's implied share price per horizon. Provisional rows use a projected (historical-CAGR) growth input rather than analyst or management guidance.
| Method | Horizon | Est. price | Multiple | Per-share input | EPS source | Confidence |
|---|---|---|---|---|---|---|
| dcf fcfe | 12M | $1.73 | — | — | Hist. CAGR | high |
| dcf fcff | 12M | $3.29 | — | — | Hist. CAGR | high |
| graham number | 12M | $2.55 | — | — | TTM | high |
| Peer EV/EBITDA | 12M | $2.78 | 5.6 | 0.22 | TTM | high |
| Peer P/FCF | 12M |
A “consensus-then vs. actual-now” overlay is on the way — what our valuation estimate said on a past date versus where the price actually landed.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
A long-thesis check that carries the widest uncertainty of the three horizons.
Top 10% on quality vs scored peers
A second lens on the 12-month fair value: for companies that score high on measured quality (profitability, balance-sheet safety, earnings stability), this read trusts more of today's profit margins instead of averaging them toward their multi-year history the way the headline number does. Shown alongside the fair value above, not in place of it. A diagnostic, not a price target or a buy/sell signal.
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
Only expensive valuation — not the full expensive x weak x turbulent stack. Regime (Mania) does not concentrate fragility.
For similar setups historically (n=20,154): about 33% saw a 20%+ drawdown, and roughly 76% of those did not recover within the year. These are historical base rates for the cohort, not a forecast of this stock.
Looks more expensive than peers.
Cheaper than its own typical valuation.
Trailing four: 2025-Q3, 2025-Q4, 2026-Q1, 2026-Q2
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
| $5.01 |
| 16.9 |
| 0.30 |
| TTM |
| high |
| Peer P/E | 12M | $6.03 | 23.2 | 0.26 | TTM | high |
| Peer P/S | 12M | $4.41 | 1.1 | 4.11 | TTM | high |
| residual income | 12M | $1.86 | — | — | TTM | high |
| Own P/E history | 12M | $10.58 | 40.7 | 0.26 | TTM | high |
| triangulated | 12M | $6.35 | 23.2 | 0.27 | Triangulated | high |
| Peer P/FCF | 3Y | $1.85 | 16.9 | 0.11 | Hist. CAGR(prov.) | medium |
| Peer P/S | 3Y | $3.23 | 1.1 | 3.01 | Hist. CAGR(prov.) | medium |
| Peer P/FCF | 5Y | $0.96 | 16.9 | 0.06 | Hist. CAGR(prov.) | medium |
| Peer P/S | 5Y | $2.10 | 1.1 | 1.96 | Hist. CAGR(prov.) | medium |